Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 49
2012 78
2013 119
2014 136
2015 238
2016 406
2017 576
2018 757
2019 726
2020 90
Text availability
Article attribute
Article type
Publication date

Search Results

2,758 results
Results by year
Filters applied: . Clear all
Page 1
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Patel SP, Kurzrock R. Patel SP, et al. Mol Cancer Ther. 2015 Apr;14(4):847-56. doi: 10.1158/1535-7163.MCT-14-0983. Epub 2015 Feb 18. Mol Cancer Ther. 2015. PMID: 25695955 Free article. Review.
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
Boussiotis VA. Boussiotis VA. N Engl J Med. 2016 Nov 3;375(18):1767-1778. doi: 10.1056/NEJMra1514296. N Engl J Med. 2016. PMID: 27806234 Free PMC article. Review. No abstract available.
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators. Carbone DP, et al. N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493. N Engl J Med. 2017. PMID: 28636851 Free PMC article.
Deubiquitination and Stabilization of PD-L1 by CSN5.
Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen CH, Sahin AA, Yu D, Hortobagyi GN, Hung MC. Lim SO, et al. Cancer Cell. 2016 Dec 12;30(6):925-939. doi: 10.1016/j.ccell.2016.10.010. Epub 2016 Nov 17. Cancer Cell. 2016. PMID: 27866850 Free PMC article.
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.
Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland I, Broeks A, Horlings HM, Wessels LFA, Blank CU, Xiao Y, Heck AJR, Borst J, Brummelkamp TR, Schumacher TNM. Mezzadra R, et al. Nature. 2017 Sep 7;549(7670):106-110. doi: 10.1038/nature23669. Epub 2017 Aug 16. Nature. 2017. PMID: 28813410 Free PMC article.
PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy.
Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, Pasdar A, Sahebkar A. Salmaninejad A, et al. J Cell Physiol. 2019 Aug;234(10):16824-16837. doi: 10.1002/jcp.28358. Epub 2019 Feb 19. J Cell Physiol. 2019. PMID: 30784085 Review.
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.
Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, Gilan O, Bloor S, Noori T, Morgens DW, Bassik MC, Neeson PJ, Behren A, Darcy PK, Dawson SJ, Voskoboinik I, Trapani JA, Cebon J, Lehner PJ, Dawson MA. Burr ML, et al. Nature. 2017 Sep 7;549(7670):101-105. doi: 10.1038/nature23643. Epub 2017 Aug 16. Nature. 2017. PMID: 28813417 Free PMC article.
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. Powles T, et al. Nature. 2014 Nov 27;515(7528):558-62. doi: 10.1038/nature13904. Nature. 2014. PMID: 25428503 Clinical Trial.
2,758 results
Jump to page
Feedback